| ID | Type | Description | Link |
|---|---|---|---|
| K01MH080992-01 | U.S. NIH Grant/Contract | View source | |
| 071529 | |||
| DNBBS 7K-TGNB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine whether various drugs affecting sleep cycles can improve different kinds of memory.
Research provides evidence for strong, specific connections between sleeping and memory. This research shows that sleeping is necessary for certain types of memories to form, certain sleep stages lead to specific types of learning and memory consolidation, and naps are as effective as night-time sleep in these learning and memory processes. Current evidence also indicates that there are different types of memory and that the different types can operate and develop independently. In this study, three different memory types will be examined: perceptual, motor, and declarative memory. Perceptual memory is measured through the ability to recognize discrete stimuli; motor memory is measured through the ability to perform specific, coordinated tasks; and declarative memory is measured through the ability to recite memorized information. Different stages in the sleep cycle correlate with improvements in each of these memory processes. For instance, improvement of perceptual memory tasks is dependent on rapid eye motion (REM) sleep; motor learning is related to sleep stage 2; and declarative memory consolidation is related to short wave sleep (SWS), which includes sleep stages 3 and 4.
New drugs can target specific sleep stages and increase the amount of time people spend in those stages when they sleep. For example, the new prescription drug zolpidem increases time spent in stage 2 during sleep, and the drug sodium oxybate increases time spent in SWS. Compared to sleep impacted by either zolpidem or sodium oxybate, normal sleep has proportionally more time spent in REM. This study will use medications, or their lack, to manipulate how much time is spent in REM, stage 2, and SWS. The study will then examine whether the percentage of sleep spent in different stages affects the learning processes associated with those stages.
Participation in this study will last 6 weeks. At the outset, participants will undergo a 2-hour screening visit that will include a medical history, a physical examination, routine lab tests, urine tests for drugs and pregnancy, an electrocardiogram, and a clinical interview for mental health. Participants will also be asked to complete a series of questionnaires on subjective sleep quality, sleep quantity, and daytime sleepiness.
Participants will complete five study visits, beginning 1 week from screening and separated by 5 to 10 days to allow drug wash-out and recovery from effects of the previous visit. Each study visit will involve an overnight stay in a sleep lab. Participants will arrive at 8 PM, go to bed at 10 PM, and be awakened at 5 AM. Between 6 and 8 AM, they will undergo three different tests, each corresponding to a different type of learning and memory process: perceptual, motor, or declarative. The test will include recognizing a target image, typing a specific finger sequence on a keyboard, and verbally recalling a list of words. Participants will receive one of the study drugs or placebo at 8:30 AM and then be allowed to take a 90-minute nap between 9 and 11 AM. They will receive a different drug, different dosage, or placebo at each study visit. Between 4 and 6 PM, they will be retested on the previous three tests. While sleeping, participants will be outfitted with sensors monitoring muscle activity, eye movements, brain waves, heart and lung functioning, and-on the first night-breathing.
For the entire duration of the study, participants will wear an actigraph, which is a wristwatch-like device that monitors sleep cycles. Participants will also be required to maintain a regular sleep schedule, going to sleep and waking up in the same 2-hour window each day. They will also report on sleep schedule and caffeine, alcohol, and drug use in a daily sleep diary. Caffeine, alcohol, and drug use will be prohibited starting at noon on the day prior to each study visit.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| zolpidem first, then placebo | Experimental | Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap. |
|
| Placebo first, then zolpidem | Placebo Comparator | Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| zolpidem | Drug | Participants will receive one dose of 10 mg before each nap. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacological Enhancement of Specific Sleep Parameters | Number of sleep spindles comparing placebo vs active drug. We count spindles in the EEG record. | Two weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of Pharmacological Interventions With Sleep-stage-specific Memory Tasks | improvement on a verbal memory task in active drug. We measured the number of words recalled. | two weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sara C. Mednick, PhD | UCSD | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCSD General Clinical Research Center Laboratory for Sleep and Chronobiology (GCRC-LSC) | La Jolla | California | 92093 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Zolpidem First, Then Placebo | Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap. |
| FG001 | Placebo First, Then Zolpidem | Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | This was a within-subjects design, so all 30 started in the participant flow, but only 28 completed all arms of the study. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Pharmacological Enhancement of Specific Sleep Parameters | Number of sleep spindles comparing placebo vs active drug. We count spindles in the EEG record. | Posted | Mean | Standard Deviation | sleep spindles | Two weeks |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Zolpidem | This arm reflects all participants who received the drug (1 dose of 10mg before each nap) during the entire course of the study. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| drowsiness | General disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Sara C. Mednick | UCSD | 8586423192 | mednicks@uci.edu |
Not provided
| ID | Term |
|---|---|
| D065853 | Spatial Learning |
| ID | Term |
|---|---|
| D013037 | Spatial Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077334 | Zolpidem |
| ID | Term |
|---|---|
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Participants will receive a dose of placebo before each nap. |
|
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Correlation of Pharmacological Interventions With Sleep-stage-specific Memory Tasks | improvement on a verbal memory task in active drug. We measured the number of words recalled. | Posted | Mean | Standard Deviation | recall of words | two weeks |
|
|
|
| 0 |
| 28 |
| 0 |
| 28 |
| 17 |
| 28 |
| EG001 | Placebo | This arm reflects all participants who received the placebo (1 dose of placebo before each nap) during the entire course of the study. | 0 | 28 | 0 | 28 | 0 | 28 |
| dizziness | General disorders | Systematic Assessment |
|
| nausea | General disorders | Systematic Assessment |
|
| vomiting | General disorders | Systematic Assessment |
|
Not provided
Not provided